Treatment Resistant Depression Clinical Trial
Official title:
Correlating Electroconvulsive Therapy Response to Electroencephalographic Ictal Complexes and Postictal Markers
Verified date | November 2023 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Single-center study to determine the relationship between changes in depression symptoms and electroencephalographic (EEG) patterns induced by electroconvulsive therapy (ECT)
Status | Active, not recruiting |
Enrollment | 31 |
Est. completion date | June 2025 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18 years or greater - Referral for ECT index course for treatment-resistant depression (unipolar major depressive disorder or bipolar depression), major depressive disorder with psychotic symptoms, schizophrenia or schizoaffective being treated for a depressed episode, unspecified depression Exclusion Criteria: - Schizophrenia or schizoaffective disorder not being treated for a depressed episode. |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine/Barnes-Jewish Hospital | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine |
United States,
Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT. 2003 Sep;19(3):139-47. doi: 10.1097/00124509-200309000-00005. — View Citation
Lopez J, Hoffmann R, Armitage R. Reduced sleep spindle activity in early-onset and elevated risk for depression. J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):934-43. doi: 10.1016/j.jaac.2010.05.014. Epub 2010 Jul 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Interval change in Quick Inventory of Depressive Symptomatology-16 Item Self Report (QIDS-SR16) between ECT sessions. | 16 item Self-report questionnaire that best describes the participant's depressive symptoms over the last seven days. Scale: 0=never or do not, 3=nearly all the time, or the highest level of time listed on the question. | Up to 8 weeks during patients ECT treatment course | |
Primary | Pittsburgh Sleep Quality Index (PSQI) | Questions relating to usual sleep habits during the past month. The first four questions are free text entry and indicate the patient's sleep experience for the majority of days and nights in the past month. The remaining questions are on a scale with 1=not during the past month, 2=less than once a week, 3=Once or twice a week, 4=Three or more times a week | Up to 8 weeks during patients ECT treatment course | |
Primary | Duration of Central Positive Complexes during ECT treatments. | Total time (in seconds) during the ictal period for which CPCs are present in the EEG immediately following seizure induction until termination of the seizure.
Range of values: 0 - 300 seconds |
Up to 8 weeks during patients ECT treatment course | |
Primary | Duration of PGES during ECT treatments. | Total time (in seconds) during the postictal period for which PGES is present in the EEG immediately following seizure termination for up to 5 minutes.
Range of values: 0 - 300 seconds |
Up to 8 weeks during patients ECT treatment course | |
Primary | Amplitude of PGES during ECT treatments. | Median rectified EEG amplitude (in microvolt) during the postictal period for which PGES is present in the EEG immediately following seizure termination for up to 5 minutes.
Range of values: 0 - 10 microvolt |
Up to 8 weeks during patients ECT treatment course | |
Primary | Density of EEG sleep spindles during first cycle of non-rapid eye movement (NREM) stages N2 on evenings following ECT treatments. | The total number of EEG sleep spindles per minute present during the first identified cycle of N2 sleep.
Range of values: 0 - 60 spindles/min |
Up to 8 weeks during patients ECT treatment course | |
Primary | Slow wave activity (SWA) during first cycle of N3 sleep on evenings following ECT treatments | Total power of EEG slow waves per minute present during the first identified cycle of N3 sleep Range of values: 0 - 50 dB/min | Up to 8 weeks during patients ECT treatment course |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04124341 -
PCS in Severe Treatment Resistant Depression
|
N/A | |
Recruiting |
NCT03887715 -
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
|
N/A | |
Completed |
NCT04727229 -
Stellate Ganglion Block for Major Depressive Disorder.
|
Phase 4 | |
Completed |
NCT04634669 -
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
|
Phase 2 | |
Withdrawn |
NCT03175887 -
Investigational TMS Treatment for Depression
|
N/A | |
Completed |
NCT03134066 -
Neurocognitive Features of Patients With Treatment-Resistant Depression
|
||
Active, not recruiting |
NCT01984710 -
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
|
N/A | |
Completed |
NCT01935115 -
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
|
Phase 4 | |
Terminated |
NCT01687478 -
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT00531726 -
Berlin Deep Brain Stimulation Depression Study
|
N/A | |
Recruiting |
NCT04041479 -
Biomarker-guided rTMS for Treatment Resistant Depression
|
Phase 3 | |
Recruiting |
NCT05870540 -
BPL-003 Efficacy and Safety in Treatment Resistant Depression
|
Phase 2 | |
Recruiting |
NCT04959253 -
Psilocybin in Depression Resistant to Standard Treatments
|
Phase 2 | |
Completed |
NCT04856124 -
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
|
||
Recruiting |
NCT03272698 -
ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression
|
Phase 4 | |
Recruiting |
NCT05680220 -
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
|
N/A | |
Completed |
NCT03288675 -
Stepped Care aiTBS 2 Depression Study (Ghent)
|
N/A | |
Recruiting |
NCT06138691 -
KET-RO Plus RO DBT for Treatment Resistant Depression
|
Phase 1 | |
Terminated |
NCT02675556 -
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
|
Phase 1 | |
Recruiting |
NCT03952962 -
Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression
|
N/A |